#Transcriptomics Data

[biomededgene]

Python-Based Pipelines for Variant Calling in Genomic Research

In the rapidly evolving field of genomics, variant calling is a cornerstone of genomic research that enables scientists to identify genetic variations associated with diseases, traits, and evolutionary processes. With the exponential growth of high-throughput sequencing technologies, researchers are now faced with vast amounts of genomic data, necessitating efficient and robust tools for analysis. Python, a versatile programming language with a rich ecosystem of libraries, has become a popular choice for developing variant calling pipelines. In this article, we will explore how to create Python-based pipelines for variant calling, focusing on the process of handling VCF files, and illustrating how Python can transform genomic data into meaningful discoveries.

To know more, visit us at: https://edgenebiomed.com/

[covid-safer-hotties]

Reference saved in our archive

Abstract Vascular disruption has been implicated in coronavirus disease 2019 (COVID-19) pathogenesis and may predispose to the neurological sequelae associated with long COVID, yet it is unclear how blood–brain barrier (BBB) function is affected in these conditions. Here we show that BBB disruption is evident during acute infection and in patients with long COVID with cognitive impairment, commonly referred to as brain fog. Using dynamic contrast-enhanced magnetic resonance imaging, we show BBB disruption in patients with long COVID-associated brain fog. Transcriptomic analysis of peripheral blood mononuclear cells revealed dysregulation of the coagulation system and a dampened adaptive immune response in individuals with brain fog. Accordingly, peripheral blood mononuclear cells showed increased adhesion to human brain endothelial cells in vitro, while exposure of brain endothelial cells to serum from patients with long COVID induced expression of inflammatory markers. Together, our data suggest that sustained systemic inflammation and persistent localized BBB dysfunction is a key feature of long COVID-associated brain fog.

[biopractify]

Free online courses for bioinformatics beginners

🔬 Free Online Courses for Bioinformatics Beginners 🚀

Are you interested in bioinformatics but don’t know where to start? Whether you're from a biotechnology, biology, or computer science background, learning bioinformatics can open doors to exciting opportunities in genomics, drug discovery, and data science. And the best part? You can start for free!

Here’s a list of the best free online bioinformatics courses to kickstart your journey.

📌 1. Introduction to Bioinformatics – Coursera (University of Toronto)

📍 Platform: Coursera 🖥️ What You’ll Learn:

Basic biological data analysis

Algorithms used in genomics

Hands-on exercises with biological datasets

🎓 Why Take It? Ideal for beginners with a biology background looking to explore computational approaches.

📌 2. Bioinformatics for Beginners – Udemy (Free Course)

📍 Platform: Udemy 🖥️ What You’ll Learn:

Introduction to sequence analysis

Using BLAST for genomic comparisons

Basics of Python for bioinformatics

🎓 Why Take It? Short, beginner-friendly course with practical applications.

📌 3. EMBL-EBI Bioinformatics Training

📍 Platform: EMBL-EBI 🖥️ What You’ll Learn:

Genomic data handling

Transcriptomics and proteomics

Data visualization tools

🎓 Why Take It? High-quality training from one of the most reputable bioinformatics institutes in Europe.

📌 4. Introduction to Computational Biology – MIT OpenCourseWare

📍 Platform: MIT OCW 🖥️ What You’ll Learn:

Algorithms for DNA sequencing

Structural bioinformatics

Systems biology

🎓 Why Take It? A solid foundation for students interested in research-level computational biology.

📌 5. Bioinformatics Specialization – Coursera (UC San Diego)

📍 Platform: Coursera 🖥️ What You’ll Learn:

How bioinformatics algorithms work

Hands-on exercises in Python and Biopython

Real-world applications in genomics

🎓 Why Take It? A deep dive into computational tools, ideal for those wanting an in-depth understanding.

📌 6. Genomic Data Science – Harvard Online (edX) 🖥️ What You’ll Learn:

RNA sequencing and genome assembly

Data handling using R

Machine learning applications in genomics

🎓 Why Take It? Best for those interested in AI & big data applications in genomics.

📌 7. Bioinformatics Courses on BioPractify (100% Free)

📍 Platform: BioPractify 🖥️ What You’ll Learn:

Hands-on experience with real datasets

Python & R for bioinformatics

Molecular docking and drug discovery techniques

🎓 Why Take It? Learn from domain experts with real-world projects to enhance your skills.

🚀 Final Thoughts: Start Learning Today!

Bioinformatics is a game-changer in modern research and healthcare. Whether you're a biology student looking to upskill or a tech enthusiast diving into genomics, these free courses will give you a strong start.

📢 Which course are you excited to take? Let me know in the comments! 👇💬

[bpod-bpod]

More Than Immunity

As skin develops before birth it's rich in innate (a first response, rather than an adapting form of defence) immune cells, including macrophages. By creating a reference atlas of pre-natal human skin (7–17 weeks post-conception), combining single-cell and spatial transcriptomics (locating active genes) data, this study finds that macrophages play a role beyond providing immunity, driving the development of vessels in the skin

Read the published research article here

Still from video from work by Nusayhah Hudaa Gopee, Elena Winheim and Bayanne Olabi, and colleagues

Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK

Video originally published with a Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

Published in Nature, October 2024

You can also follow BPoD on Instagram, Twitter and Facebook

[longhaulerbear]

Here we show that BBB disruption is evident during acute infection and in patients with long COVID with cognitive impairment, commonly referred to as brain fog. Using dynamic contrast-enhanced magnetic resonance imaging, we show BBB disruption in patients with long COVID-associated brain fog. Transcriptomic analysis of peripheral blood mononuclear cells revealed dysregulation of the coagulation system and a dampened adaptive immune response in individuals with brain fog. Accordingly, peripheral blood mononuclear cells showed increased adhesion to human brain endothelial cells in vitro, while exposure of brain endothelial cells to serum from patients with long COVID induced expression of inflammatory markers. Together, our data suggest that sustained systemic inflammation and persistent localized BBB dysfunction is a key feature of long COVID-associated brain fog.

[nullarysources]

Astronauts face health risks—even on short trips in space

Ramin Skibba for Science:

In 2021, four passengers, including billionaire businessman Jared Isaacman, rode into space on a SpaceX rocket, orbiting Earth for 3 days in the company's Dragon capsule before splashing down in the Atlantic Ocean. The trip, financed by Isaacman and called Inspiration4, was the first privately funded orbital mission on a private rocket carrying private citizens—setting the stage for more routine tourist space travel today.

The astronauts also underwent intensive medical monitoring before, during, and after their flight. Now, researchers have analyzed how the space radiation and weightlessness they experienced affected their bodies, releasing a package of more than 40 studies, most of them based on Inspiration4 data. Published today in Nature journals, the Space Omics and Medical Atlas (SOMA) includes studies of the participants' genomes, microbiomes, transcriptomes (the messenger RNA made from their genes), and proteomes (their panoply of proteins).

…

One message from the SOMA studies, Mason says, is that the same health effects that professional astronauts experience over their long expeditions turn up among space tourists who only spend a few days in orbit.

You mean I can go to space recreationally and still suffer negative health effects? Sign me up immediately

[prachicmi2]

Spatial Genomics Transcriptomics Market is growing amid VC Funding Surge

Market size and Overview The Spatial Genomics Transcriptomics Market is witnessing a robust influx of venture capital and strategic alliances.

The Global Spatial Genomics Transcriptomics Market size is estimated to be valued at USD 335.8 Mn in 2025 and is expected to reach USD 790 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 13% from 2025 to 2032. Cutting-edge single-cell mapping technologies and spatial multiomics integration are driving this expansion. Our detailed Spatial Genomics Transcriptomics Market Insights report underscores the rise of spatial proteomics and in situ sequencing segments, shaping future market dynamics. This market report consolidates comprehensive market research and real-world data to refine growth strategies and anticipate market opportunities. By 2032, sustained market growth and increased market size will reflect accelerated industry adoption. Get more insights on,Spatial Genomics Transcriptomics Market

[bisresearch0]

Spatiotemporal Omics Market: Growth Trends, Technologies, and Future Forecast

What is spatiotemporal omics?

Spatiotemporal omics is an advanced approach in molecular biology that integrates spatial and temporal dimensions into multi-omics analyses (e.g., genomics, transcriptomics, proteomics, metabolomics). This technique enables the mapping of biomolecular changes within the precise anatomical context of tissues over time, offering unprecedented resolution into how cellular behavior evolves in health and disease. It has transformative potential in areas such as oncology, neuroscience, immunology, and developmental biology, driving innovation in precision medicine and systems biology.

The Spatio OMICS Market is expected to grow at a significant rate due to advancements in sequencing and imaging technologies, and expansion of research and development funding.

Which technologies are driving the spatiotemporal omics market?

Spatial Transcriptomics – Maps gene expression in tissue context

Spatial Proteomics – Visualizes protein distribution

Mass Spectrometry Imaging (MSI) – Detects molecules with spatial precision

Single-Cell RNA Sequencing (scRNA-seq) – Captures temporal changes at cell level

Multiplexed Imaging (e.g., CODEX, MIBI) – Analyzes many biomarkers in tissues

What are the current limitations or challenges in spatiotemporal omics adoption?

High Technology Costs: The advanced instruments and reagents required for spatiotemporal omics are costly, making adoption challenging for many academic and smaller research institutions. This financial barrier limits access despite rising interest in spatial biology.

Complexity of Data Analysis: Spatiotemporal omics generate vast, high-dimensional datasets combining molecular and imaging data. Processing this information demands specialized software, computational infrastructure, and bioinformatics expertise. Without these, deriving actionable insights can be slow and resource-intensive.

Limited Skilled Workforce and Infrastructure: The field requires interdisciplinary skills in molecular biology, spatial imaging, and data science. However, a shortage of trained professionals and inadequate infrastructure in many regions slows down adoption and implementation across research and clinical environments.

To get detailed information on Spatiotemporal OMICS Industry, Click here!

Which regions are investing heavily in spatiotemporal omics research and development?

North America

Europe

Asia-Pacific

Latin America

Who are the leading players in the spatiotemporal omics industry?

10x Genomics

NanoString Technologies

Akoya Biosciences

Bruker Corporation

Vizgen

RareCyte

For a comprehensive analysis, refer to the full report by BIS Research: Spatiotemporal OMICS Market.

End Use Insights

Innovation Strategy: It identifies opportunities for market entry and technology adoption, helping organizations stay ahead of the competition while meeting evolving customer demands.

Growth Strategy: The report outlines targeted growth strategies to optimize market share, enhance brand presence, and drive revenue expansion.

Competitive Strategy: It evaluates key competitors and offers practical guidance for maintaining a competitive edge in a rapidly evolving market.

Conclusion

The market for spatiotemporal omics is expected to increase significantly due to growing applications in clinical and research settings, growing need for precision medicine, and technical advancements. To keep a competitive edge, major competitors in the market are always improving their product offerings, investing in R&D, and inventing. Despite obstacles like exorbitant expenses and intricate data, the amalgamation of artificial intelligence and multi-modal platforms offers significant prospects. Organizations that use these insights can take advantage of development opportunities, overcome obstacles, and set themselves up for long-term success in the ever-changing spatiotemporal omics landscape.

[freyrgri]

Evaluating the Global Business Impact of U.S. Restrictions on Cross-Border Data Access

Overview

As of 2025, the United States of America has introduced sweeping restrictions on cross-border access to sensitive personal data under 28 CFR Part 202, affecting global clinical research, biotech, and digital health operations. The regulation targets data sharing and access involving six countries of concern: China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela, and applies even when access is indirect or data is anonymized.

This article outlines the scope of regulated data, highlights prohibited and restricted transactions, and explores the real-world impact on clinical trials, data storage, outsourcing, and international partnerships. It also reviews key exemptions, such as those for FDA-regulated studies, and provides actionable recommendations for companies to remain compliant in a shifting global data governance landscape.Regulation28 CFR Part 202Issued byU.S. Department of Justice (DOJ)Based onExecutive Order 14117 (Feb 28, 2024)ScopeLimits foreign access to U.S. sensitive personal and government-related data by certain foreign governments or associated personsApplies toLegally binding restrictions on U.S. persons interacting with foreign entities or individualsPublishedJanuary 8, 2025EffectiveApril 8, 2025 (90 days after publication)[Note: Entities must comply with the Rule’s due diligence, audit and reporting requirements by October 5, 2025. The Rule does not apply to transactions completed before its effective date, but it does apply to ongoing activity, even if that activity is required by prior contracts.]

Geographic and Individual Impact

Companies engaging with Contract Research Organizations (CROs), labs, IT vendors, or collaborators from the following six countries must reassess data access and control. Any involvement, even indirectly could trigger restrictions under this rule:

China (including Hong Kong and Macau)

Russia

Iran

North Korea

Cuba

Venezuela

Entities that are:

50% or more owned (directly or indirectly) by one or more countries of concern, or

Organised under the laws of, or principally operating from, a country of concern.

50% or more owned (directly or indirectly) by other covered persons, including those described below.

Individuals who are:

Employees or contractors of either a country of concern or of any of the entities described above.

Are primarily residents within the territorial jurisdiction of a country of concern.

Any person, regardless of location, who is determined by the U.S. Attorney General to:

Be owned or controlled by, or subject to the jurisdiction or direction of, a country of concern or covered person,

Be acting or likely to act on behalf of a country of concern or covered person, or

Have knowingly caused or directed a violation of this regulation or be likely to do so.

Types of Regulated Data

The regulation covers “bulk U.S. sensitive personal data” as defined in §202.206—referring to large volumes of personal information about U.S. individuals, regardless of format or whether it has been anonymized, pseudonymized, de-identified, or encrypted. Coverage applies when volume thresholds in §202.205 are met or exceeded. This includes:

Genomic and ‘omic’ data: Including genomic, epigenomic, proteomic, or transcriptomic information

Biometric Identifiers: Including facial images, voice patterns, retina scans, and similar features

Personal Health Data: This includes physical measurements (e.g., height, weight, vital signs), symptoms, psychological or behavioural information, medical diagnoses, treatments, and test results

Personal Financial Data: This covers credit or debit card details, bank account information, financial liabilities, and payment history

Precise Geolocation Data: This refers to past or present location data that can identify the physical location of a person or device within about 1,000 meters (roughly two-thirds of a mile)

Multiple Identifying Elements: This includes two or more means of identification such as IMEI numbers, MAC addresses, SIM card numbers, Social Security numbers, driver’s licenses, or other government-issued IDs

Government-related data is separately defined under §202.222 and includes any data that could reveal information about federal personnel or sensitive government locations.

Restricted or Prohibited Data

Prohibited transactions

U.S. persons/entities (i.e. any U.S. citizen, national, lawful permanent resident, refugee, or asylee; any person located in the U.S.; or any entity organized under U.S. law (including foreign branches)) must avoid the following:

Selling or sharing sensitive data with entities or individuals linked to the six restricted countries

Sending human biospecimens or genomic data to partners in those countries

Setting up vendor or employment deals that give foreign actors access to sensitive U.S. data

For example, if a U.S.-based genomics company develops an AI tool trained on a large volume of sensitive U.S. genomic data, and later licenses that tool to its parent company in China, this could be considered a prohibited transaction. Even if the tool itself does not directly share raw data, the potential to reveal sensitive training data, combined with the U.S. company’s awareness of this risk, constitutes indirect access by a covered foreign person, which is restricted under the regulation.

Restricted Transactions

Some activities with vendors, employees, or investors from the six restricted countries can proceed only if specific security requirements are met. These include agreements where sensitive data may be accessed directly or indirectly.

Applies to:

Vendor contracts (e.g. cloud hosting, data processing)

Employment agreements (e.g. IT support, data handling)

Investment relationships with data access components

These are not allowed unless the U.S. company fully implements the required data safeguards. Simply using “equivalent” controls is not enough.

Take for instance a U.S.-based life sciences company that needs help maintaining its clinical data platform. To cut costs or find specific skills, it hires a remote IT contractor who happens to be based in a restricted country. Even if the contractor is only working on the back end, there is still a risk; they could potentially access sensitive U.S. personal health or financial data. In a situation like this, the company is required to have a full set of security measures in place. If it does not, the arrangement would violate 28 CFR Part 202. It does not matter that the contractor is not supposed to see the data, what matters is that the access risk exists.

Exemptions Relevant to Clinical Research

Allowed (with conditions)Not AllowedFDA-regulated clinical investigations, including clinical trialsNon-FDA/non-federally funded studies unless specifically licensedOther clinical investigations and post-marketing surveillance with de-identified dataStudies where data can be re-identified or accessed by covered entities

Current impact: As of April 2025, the National Institutes of Health (NIH) has barred researchers affiliated with the six countries of concern accessing 21 major U.S. biomedical datasets, enforcing provisions of 28 CFR Part 202. (Science, 2025)

Potential Impact

The regulation has direct implications for:

Clinical trials and R&D: Collaborating on cross-border studies with labs, CROs, or cloud providers in restricted countries risks regulatory violations. Even if the data is encrypted, access by these parties may still be subject to restrictions.

Data storage and processing: Clients using foreign infrastructure or outsourced IT in these regions must reassess vendor arrangements and consider relocating or segmenting data.

Hiring and partnerships: Employment involving sensitive data access by personnel in these countries may need restrictions or licensing.

Recommendations

Assess Exposure: Identify clinical trials, data transfers, or collaborations involving restricted countries, including CROs, labs, cloud vendors, and academics.

Verify Exemptions and Seek Licensing: Confirm if activities qualify for exemptions (e.g., FDA-regulated or de-identified studies) and maintain compliance documentation. For non-exempt activities, consult legal counsel to apply for DOJ licenses.

Control Data Access: Implement technical and legal controls to prevent unauthorized access; audit data systems regularly.

Adapt and Monitor: Favor exempt collaborations, minimize data sharing, and stay updated on DOJ guidance and enforcement.

Conclusion

In conclusion, the U.S. restrictions on foreign access to sensitive data signal a pivotal shift in global data governance, including for industries involved in clinical research, biotechnology, and digital health. As enforcement intensifies, organizations must take a proactive, risk-based approach, assessing exposure, verifying exemptions, securing data access, and documenting compliance efforts. By adapting operations and strengthening internal controls, businesses can protect sensitive U.S. data, uphold regulatory obligations, and maintain the integrity of their global collaborations.

Original Source: U.S. Data Access Restrictions & Their Global Business Impact

[elucidata]

Best Practices for Biomarker Discovery Using Transcriptomics Data

Molecular biomarkers have the potential to greatly enhance efficiency and precision in clinical decision-making. Common methods for deriving these biomarkers include feature selection, machine learning (ML), and statistical modeling.

Source Link

[aimarketresearch]

Tumor Transcriptomics Market Size, Share, Trends, Demand, Growth and Competitive Analysis

Executive Summary  Tumor Transcriptomics Market:

This international Tumor Transcriptomics Market business report includes strategic profiling of key players in the market, systematic analysis of their core competencies, and draws a competitive landscape for the market. It is the most appropriate, rational and admirable market research report provided with a devotion and comprehension of business needs. The report also estimates CAGR (compound annual growth rate) values along with its fluctuations for the definite forecast period. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the market has also been included in this market report. It all together leads to the company’s growth, by subsidizing the risk and improving the performance.

Competitive landscape in this report covers strategic profiling of key players in the market, comprehensively analyzing their core competencies, and strategies. According to this Tumor Transcriptomics Market report, the global market is anticipated to witness a moderately higher growth rate during the forecast period. This Tumor Transcriptomics Market report is structured with the clear understanding of business goals of  industry and needs to bridge the gap by delivering the most appropriate and proper solutions. Businesses can confidently rely on the information mentioned in this Tumor Transcriptomics Market report as it is derived only from the important and genuine resources.

Discover the latest trends, growth opportunities, and strategic insights in our comprehensive Tumor Transcriptomics Market report. Download Full Report: https://www.databridgemarketresearch.com/reports/global-tumor-transcriptomics-market

Tumor Transcriptomics Market Overview

**Segments**

- **By Product Type**: The tumor transcriptomics market can be segmented into instruments, consumables, and services. Instruments include PCR machines, microarray equipment, and sequencing platforms. Consumables consist of reagents, RNA extraction kits, and assay kits. Services cover gene expression profiling, data analysis, and consulting services.

- **By Cancer Type**: This market segment is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. Each cancer type may require specific transcriptomic analysis for targeted therapies and personalized medicine.

- **By End-User**: The tumor transcriptomics market can be further divided into hospitals, cancer research centers, diagnostic laboratories, and pharmaceutical companies. Different end-users have varying needs for transcriptomic tools and services.

- **By Region**: Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Each region has its own set of regulations, healthcare infrastructure, and adoption rates for tumor transcriptomics technology.

**Market Players**

- **Illumina, Inc.**: One of the key players in the tumor transcriptomics market, Illumina offers sequencing platforms and related services for cancer research and diagnostics.

- **Thermo Fisher Scientific Inc.**: This company provides a wide range of consumables and instruments for tumor transcriptomics analysis, catering to the needs of researchers and healthcare professionals.

- **Agilent Technologies**: Known for its microarray platforms and assay kits, Agilent Technologies is a major player in the global tumor transcriptomics market, offering solutions for gene expression profiling.

- **QIAGEN N.V.**: QIAGEN specializes in RNA extraction kits and bioinformatics tools essential for tumor transcriptomics, enabling researchers to analyze gene expression patterns in cancer.

- **Fluidigm Corporation**: With its innovative microfluidic technology, Fluidigm Corporation offers high-throughput solutions for single-cell analysis and gene expression studies in tumors.

The global tumor transcriptomics market is witnessing significant growth due to the rising prevalence of cancer worldwide and the increasing demand for precision medicine. Advancements in transcriptomic technologies, such as next-generation sequencing and microarray analysis, have enabled researchers to study gene expression patterns in tumors with high accuracy and throughput. Key market players are investing in product development, strategic collaborations, and expansion initiatives to capitalize on the growing opportunities in this market. As personalized medicine gains momentum, the use of tumor transcriptomics for patient stratification and treatment selection is expected to drive further market growth.

Market players such as Illumina, Thermo Fisher Scientific Inc., Agilent Technologies, QIAGEN N.V., and Fluidigm Corporation are at the forefront of developing cutting-edge solutions for tumor transcriptomics. These companies offer a wide range of instruments, consumables, and services that cater to the diverse needs of hospitals, cancer research centers, diagnostic laboratories, and pharmaceutical companies. By focusing on product development and strategic collaborations, these key players are driving innovation in the market and expanding their global footprint.

In addition to technological advancements, the market is also influenced by regulatory landscapes and healthcare infrastructure in different regions. North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa each have unique market dynamics that shape the adoption and growth of tumor transcriptomics technology. Market players must navigate these regional differences to effectively penetrate local markets and capitalize on the growing demand for precision medicine solutions.

Advancements in transcriptomic technologies, such as next-generation sequencing, microarray analysis, and RNA extraction kits, have revolutionized the way researchers study gene expression patterns in tumors. This enhanced accuracy and throughput have paved the way for more precise cancer treatments, driving the demand for transcriptomic analysis tools and services across different cancer types. The shift towards personalized medicine, which relies heavily on tumor transcriptomics to identify specific gene expression patterns for tailored treatment decisions, is a key trend shaping the market dynamics.

Furthermore, while technological innovation remains a key driver of market growth, regional dynamics also play a crucial role in shaping the adoption and expansion of tumor transcriptomics technology. Different regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa have unique regulatory landscapes and healthcare infrastructures that impact market dynamics. Market players must navigate these regional differences effectively to tap into local markets and capitalize on the increasing demand for precision medicine solutions.

Looking ahead, the global tumor transcriptomics market is expected to maintain its upward trajectory as the emphasis on personalized medicine grows and the need for targeted therapies for different cancer types intensifies. Researchers and healthcare professionals are increasingly relying on transcriptomic analysis to gain a better understanding of cancer biology and develop innovative treatment strategies. Key market players will continue to drive innovation through strategic initiatives such as product launches, collaborations, and mergers, reinforcing their position in this competitive and rapidly evolving market landscape.

The Tumor Transcriptomics Market is highly fragmented, featuring intense competition among both global and regional players striving for market share. To explore how global trends are shaping the future of the top 10 companies in the keyword market.

Learn More Now: https://www.databridgemarketresearch.com/reports/global-tumor-transcriptomics-market/companies

DBMR Nucleus: Powering Insights, Strategy & Growth

DBMR Nucleus is a dynamic, AI-powered business intelligence platform designed to revolutionize the way organizations access and interpret market data. Developed by Data Bridge Market Research, Nucleus integrates cutting-edge analytics with intuitive dashboards to deliver real-time insights across industries. From tracking market trends and competitive landscapes to uncovering growth opportunities, the platform enables strategic decision-making backed by data-driven evidence. Whether you're a startup or an enterprise, DBMR Nucleus equips you with the tools to stay ahead of the curve and fuel long-term success.

Regional Analysis/Insights

The Tumor Transcriptomics Market is analyzed and market size insights and trends are provided by country, component, products, end use and application as referenced above.

The countries covered in the Tumor Transcriptomics Market reportare U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominatesthe Tumor Transcriptomics Market because of the region's high prevalence Tumor Transcriptomics Market

Asia-Pacific is expectedto witness significant growth. Due to the focus of various established market players to expand their presence and the rising number of surgeries in this particular region.

Browse More Reports:

Global Respiratory Syncytial Virus Treatment Market Global Resorcinol Market Global Refrigerated Vending Machine Market Global Recliner Sofas Market Global Railway Operation Management Market Global Radio Frequency (RF) Components Market Global Rabies Diagnostics Market Global PVC Additives Market Global Puerperal Sepsis Treatment Market Global Pregnancy Pillow Market Global Power Inductor Market Global Powdered Seaweed Market Global Potassium carbonate Market Global Portable Fabric Canopies Market Global Polyurethane Foam Market Global Polysulfide Market Global Polyoxymethylene (POM) Market Global Polyolefin Market Global Polyethylene Terephthalate (PET) Stretch Blow Molding Machines Market Global Polyethylene (PE) Foam Film Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us: Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC : +653 1251 975 Email:- corporatesales@databridgemarketresearch.com

Tag

Tumor Transcriptomics Market Size, Tumor Transcriptomics Market Share, Tumor Transcriptomics Market Trend, Tumor Transcriptomics Market Analysis, Tumor Transcriptomics Market Report, Tumor Transcriptomics Market Growth,  Latest Developments in Tumor Transcriptomics Market, Tumor Transcriptomics Market Industry Analysis, Tumor Transcriptomics Market Key Player, Tumor Transcriptomics Market Demand Analysis

[covid-safer-hotties]

Arthritis medications could reverse COVID lung damage - Published Sept 6, 2024

Arthritis drugs already available for prescription have the potential to halt lingering lung problems that can last months or years after COVID-19 infections, new research from the University of Virginia School of Medicine and Cedars-Sinai suggests.

By examining damaged human lungs and developing an innovative new lab model, the scientists identified faulty immune processes responsible for the ongoing lung issues that plague an increasing number of people after they've otherwise recovered from COVID-19. These lasting harms of COVID infection, known as "post-infection lung fibrosis," have no good treatments. The new research, however, suggests that existing drugs such as baricitinib and anakinra can disrupt the malfunctioning immune response and finally allow damaged lungs to heal.

"Using advanced technologies like spatial transcriptomics and sophisticated microscopy, we compared lung tissues from patients and animal models we developed in the lab. We found that malfunctioning immune cells disrupt the proper healing process in the lungs after viral damage. Importantly, we also identified the molecules responsible for this issue and potential therapeutic options for patients with ongoing lung damage."

"'Spatial-omics' are state-of-the-arts technologies that can measure the molecular features with spatial location information within a sample," explained researcher Chongzhi Zang, PhD, of UVA's Department of Genome Sciences. "This work demonstrates the power of spatial transcriptomics combined with data science approaches in unraveling the molecular etiology of long COVID."

The researchers note that the findings could prove beneficial not just for lung scarring from COVID but for lung fibrosis stemming from other sources as well.

"This study shows that treatments used for the acute COVID-19 disease may also reduce the development of chronic sequelae, including lung scarring," said Peter Chen, MD, the Medallion Chair in Molecular Medicine and interim chair of the Department of Medicine at Cedars-Sinai. "Our work will be foundational in developing therapies for lung fibrosis caused by viruses or other conditions."

Understanding COVID-19 lung damage The researchers – led by Sun, Chen and Zang – wanted to better understand the cellular and molecular causes of the lingering lung problems that can follow COVID infections. These problems can include ongoing lung damage and harmful inflammation that persists well after the COVID-19 virus has been cleared from the body.

The researchers began by examining severely damaged lungs from transplant patients at both UVA and Cedars-Sinai. None of the patients had a lung disease that would have required a transplant prior to contracting COVID-19, so the scientists were hopeful that the lungs would provide vital clues as to why the patients suffered such severe lung damage and persistent fibrosis. Using the insights they obtained, the scientists then developed a new mouse model to understand how normally beneficial immune responses were going awry.

The researchers found that immune cells known as CD8+ T cells were having faulty interactions with another type of immune cell, macrophages. These interactions were causing the macrophages to drive damaging inflammation even after the initial COVID-19 infection had resolved, when the immune system would normally stand down.

The scientists remain uncertain about the underlying trigger for the immune malfunction – the immune system may be responding to lingering remnants of the COVID-19 virus, for example, or there could be some other cause, they say.

The new research suggests that this harmful cycle of inflammation, injury and fibrosis can be broken using drugs such as baricitinib and anakinra, both of which have already been approved by the federal Food and Drug Administration to treat the harmful inflammation seen in rheumatoid arthritis and alopecia, a form of hair loss.

While more study is needed to verify the drugs' effectiveness for this new purpose, the researchers hope their findings will eventually offer patients with persistent post-COVID lung problems much-needed treatment options.

"Tens of millions of people around the world are dealing with complications from long COVID or other post-infection syndromes," Sun said. "We are just beginning to understand the long-term health effects caused by acute infections. There is a strong need for more basic, translational and clinical research, along with multi-disciplinary collaborations, to address these unmet needs of patients.

Journal reference: Narasimhan, H., et al. (2024). An aberrant immune–epithelial progenitor niche drives viral lung sequelae. Nature. doi.org/10.1038/s41586-024-07926-8 www.nature.com/articles/s41586-024-07926-8

[nuadox]

AI tool finds gene groups behind complex diseases and could help create personalized treatments

- By Nuadox Crew -

Northwestern University biophysicists have developed a new AI-powered tool to identify gene combinations that cause complex diseases like cancer, diabetes, and asthma.

Unlike single-gene disorders, these illnesses result from multiple genes interacting, making them harder to study.

The new model, called TWAVE (Transcriptome-Wide conditional Variational auto-Encoder), uses generative AI to amplify limited gene expression data and detect patterns linked to disease traits.

Rather than focusing on individual genes, TWAVE identifies gene groups responsible for shifting cells between healthy and diseased states. It also considers gene expression, which reflects environmental and lifestyle factors and avoids privacy concerns associated with DNA sequences.

In tests across various diseases, TWAVE outperformed traditional methods by pinpointing disease-causing genes—including some previously missed—and showing that different people can develop the same disease from different genetic pathways.

This paves the way for more personalized treatments based on an individual's specific gene expression profile.

Header image credit: Camila Felix.

Scientific paper: Motter, Adilson E., Generative prediction of causal gene sets responsible for complex traits, Proceedings of the National Academy of Sciences (2025). DOI: 10.1073/pnas.2415071122. doi.org/10.1073/pnas.2415071122

Read more at Northwestern University

Related Content

Scientists devise statistical framework for genetically mapping autoimmune diseases

Other Recent News

Mushrooms inspire next-gen materials: Researchers decode the microscopic filaments of fungi, offering a natural blueprint for creating stronger, more sustainable materials.

[prateekcmi]

Third Generation Sequencing Market to Surpass Expectations Owing to Rising Genomic Applications

The Third Generation Sequencing Market delivers cutting-edge platforms that read long DNA or RNA fragments in real time, driving faster and more accurate genomic analyses. These systems leverage single-molecule real-time (SMRT) technology and nanopore sequencing to overcome limitations of earlier methods reducing library preparation steps and minimizing PCR bias. Researchers and clinical laboratories routinely adopt these products to resolve complex genomic regions, detect structural variants, and enable transcriptome profiling with unprecedented read lengths. Integration with bioinformatics pipelines further enhances data interpretation, fostering better diagnosis and personalized therapies.

Get More Insights on Third Generation Sequencing Market https://www.patreon.com/posts/third-generation-130505660